导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.98% | 1139/4773 |
| 近一周 | -2.19% | 1449/5462 |
| 近一月 | -7.75% | 3957/5421 |
| 近一季 | -6.64% | 2156/5209 |
| 近半年 | -1.31% | 1548/4920 |
| 近一年 | 11.88% | 882/4366 |
| 近两年 | 97.08% | 624/2954 |
| 近三年 | 73.04% | 276/2253 |
| 成立以来 | 120.95% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.76% 1947/4961 |
27.98% 1018/5312 |
- - |
- - |
| 2025 | 47.32% 570/4813 |
2.11% 1463/3635 |
1.83% 2106/4076 |
42.63% 685/4524 |
-0.66% 2589/4813 |
| 2024 | 14.79% 1005/3463 |
-0.91% 1153/2808 |
-0.57% 788/3014 |
12.47% 2338/3129 |
3.59% 797/3463 |
| 2023 | -1.09% 492/2656 |
15.16% 219/2280 |
-0.10% 361/2385 |
-10.20% 1971/2515 |
-4.25% 932/2655 |
| 2022 | -24.45% 1217/2207 |
-17.04% 1172/1919 |
3.79% 1091/2016 |
-15.38% 1280/2113 |
3.70% 656/2208 |
| 2021 | 16.97% 252/1822 |
-3.81% 827/1255 |
14.50% 252/1330 |
-2.25% 558/1466 |
8.64% 145/1822 |
| 2020 | - - |
- - |
22.34% 211/1067 |
13.44% 320/1164 |
8.61% 665/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华泰柏瑞中证科技ETF联接A VS. 长安沪深300非周期A(740101) |